Table of Contents Table of Contents
Previous Page  9 / 49 Next Page
Information
Show Menu
Previous Page 9 / 49 Next Page
Page Background

Enrollment period:

Sep. 2012~May. 2015

All efficacy analyses were conducted on the ITT population (all randomized patients).

ITT, intend to treat, Tx, treatment, PD, disease progression

* No study medication received

Enrolled n=102

Abstract ID: 8717

No study medication received

n=1

Major Protocol Violation

n=4

– No R0 resection

n=3

– Critical assessment deficiency

n=1

No study medication received

n=8

Major Protocol Violation

n=11

– No R0 resection

n=5

– Critical assessment deficiency

n=3

– Prior anti-neoplastic Tx

n=1

– Metastatic before study Tx *

n=1

– Other anti-neoplastic Tx before PD

n=1

Randomized to Erlotinib n=51

Randomized to Chemotherapy n=51

Available for primary analysis

ITT analysis population

n=51

Safety analysis population

n=50

Per-protocol population

n=46

Available for primary analysis

ITT analysis population

n=51

Safety analysis population

n=43

Per-protocol population

n=33

Efficacy and Safety of Erlotinib vs Vinorelbine/Cisplatin as Adjuvant Therapy for Stage IIIA

EGFR

Mutant NSCLC Patients (EVAN, NCT01683175)